News Search Results
Aug 07, 2025, 07:00 ET REGENXBIO Announces Pivotal Program for Surabgene Lomparvovec in Diabetic Retinopathy
treatment or retinal laser; surgical treatment may be required for advanced PDR.2 ABOUT REGENXBIO Inc.REGENXBIO is a biotechnology company on a mission to improve lives through the curative potential of gene therapy. Since its founding in 2009, REGENXBIO has pioneered the field
More news about: REGENXBIO Inc.
Aug 07, 2025, 06:45 ET Lilly reports second-quarter 2025 financial results and raises guidance
life-changing discoveries for nearly 150 years, and today our medicines help tens of millions of people across the globe. Harnessing the power of biotechnology, chemistry and genetic medicine, our scientists are urgently advancing new discoveries to solve some of the world's most significant health challenges:
More news about: Eli Lilly and Company
Aug 07, 2025, 06:30 ET Immunic, Inc. Reports Second Quarter 2025 Financial Results and Provides Corporate Update
Immunic, Inc. (Nasdaq: IMUX), a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for chronic inflammatory and autoimmune diseases, today
More news about: Immunic, Inc.
Aug 07, 2025, 06:30 ET Nuvalent Highlights Pipeline and Business Achievements, Reiterates Key Anticipated Milestones, and Reports Second Quarter 2025 Financial Results
Oliger to its board of directors. Ms. Oliger brings more than 30 years of commercial and business experience in the pharmaceutical and biotechnology industry to the Nuvalent board. Most recently, Ms. Oliger served as Senior Vice President of the Oncology Business Unit at Genentech, where she
More news about: Nuvalent, Inc.
Aug 07, 2025, 06:25 ET Lilly's oral GLP-1, orforglipron, delivers weight loss of up to an average of 27.3 lbs in first of two pivotal Phase 3 trials in adults with obesity
life-changing discoveries for nearly 150 years, and today our medicines help tens of millions of people across the globe. Harnessing the power of biotechnology, chemistry and genetic medicine, our scientists are urgently advancing new discoveries to solve some of the world's most significant health challenges:
More news about: Eli Lilly and Company
Aug 07, 2025, 01:00 ET Intas Pharmaceuticals and Accord BioPharma Become One of the Largest Global Suppliers of Pegfilgrastim with Acquisition of UDENYCA®
masses in India. Intas' biosimilars are manufactured at Intas Pharmaceuticals' European Union- Good Manufacturing Practices (EU-GMP) certified biotechnology plant located near Ahmedabad, Gujarat. For more information, visit
More news about: Accord Healthcare
Aug 06, 2025, 19:56 ET XtalPi and DoveTree Announce Landmark $6 Billion AI Drug Discovery Collaboration
intelligence (AI) and robotics for drug and materials discovery, announced a transformative strategic collaboration with DoveTree Medicines, a biotechnology pioneer founded by renowned drug developer Dr. Gregory Verdine. The collaboration, worth up to $5.99
More news about: XtalPi Inc.
Aug 06, 2025, 16:30 ET Essa Pharma Inc. Announces US$80 Million Cash Distribution to Shareholders
is being held to consider and approve the Company's previously announced transaction with XenoTherapeutics, Inc. ("Xeno"), a non-profit biotechnology company, under which Xeno will acquire all of the issued and outstanding Common Shares (the "Transaction"), which meeting is expected to
More news about: ESSA Pharma Inc.
Aug 06, 2025, 16:30 ET Corteva Delivers Strong 1H 2025, Raises Full-Year Guidance
commercialize the company's pipeline; (iii) effect of the degree of public understanding and acceptance or perceived public acceptance of the company's biotechnology and other agricultural products; (iv) effect of changes in agricultural and related policies of governments and international organizations; (v)
More news about: Corteva Agriscience
Aug 06, 2025, 16:06 ET Freenome Announces Exclusive License Agreement with Exact Sciences to Commercialize Freenome's Blood-Based Screening Test for Colorectal Cancer
BRISBANE, Calif., Aug. 6, 2025 /PRNewswire/ -- Freenome, a biotechnology company pioneering an early cancer detection platform, today announced an exclusive license agreement with Exact Sciences to advance the commercialization
More news about: Freenome Holdings, Inc.
Aug 06, 2025, 12:16 ET Clara Jensen Joins Rubin and Rudman's Trusts and Estates Group
Rubin and Rudman serves national and international companies, including large public companies and closely held businesses; real estate developers; biotechnology, pharmaceutical and medical device makers; regulated industries, public entities and municipalities; insurance companies and their insureds; educational
More news about: Rubin and Rudman
Aug 06, 2025, 11:12 ET Advanced In Vivo Efficacy Models for Preclinical Success, Upcoming Webinar Hosted by Xtalks
the global life science, food, healthcare and medical device communities. Every year, thousands of industry practitioners (from pharmaceutical, biotechnology, food, healthcare and medical device companies, private & academic research institutions, healthcare centers, etc.) turn to Xtalks for access
More news about: Xtalks
Aug 06, 2025, 10:45 ET Biomarkers Market to Grow at a CAGR of 12.3% from 2025 to 2032 | SkyQuest Technology Consulting
treatment plans to individual genetic profiles, improving efficacy and minimizing side effects.By end user, pharmaceutical and biotechnology companies dominate since they invest heavily in biomarker development to accelerate drug discovery, clinical trials, and market approvals.Buy
More news about: SkyQuest Technology
Aug 06, 2025, 10:29 ET Intas Pharmaceuticals and Accord BioPharma Become One of the Largest Global Suppliers of Pegfilgrastim with Acquisition of UDENYCA®
masses in India. Intas' biosimilars are manufactured at Intas Pharmaceuticals' European Union- Good Manufacturing Practices (EU-GMP) certified biotechnology plant located near Ahmedabad, Gujarat. For more information, visit
More news about: Intas Pharmaceuticals Ltd
Aug 06, 2025, 10:01 ET Pharmaceutical Suppositories Market is expected to generate a revenue of USD 2.74 Billion by 2032, Globally, at 5.91% CAGR: Verified Market Research®
(Genomics, Transcriptomics, Proteomics, Metabolomics), By Deployment Mode (Public Cloud, Private Cloud, Hybrid Cloud), By End User (Pharmaceutical and Biotechnology Companies, Academic and Research Institutes, Hospitals and Clinics), By Geography, And Forecast
More news about: Verified Market Research
Aug 06, 2025, 10:01 ET New Report Forecasts $1.8B Helicopter Hoists Winches and Hooks Market by 2031, Fueled by EMS and Aerial Firefighting | The Insight Partners
syndicated and consulting research services. We specialize in semiconductor and electronics, aerospace and defense, automotive and transportation, biotechnology, healthcare IT, manufacturing and construction, medical devices, technology, media and telecommunications, and chemicals and materials. Contact
More news about: The Insight Partners
Aug 06, 2025, 10:00 ET Pomerantz Law Firm Announces the Filing of a Class Action Against PepGen Inc. and Certain Officers - PEPG
[Click here for information about joining the class action] PepGen is a clinical-stage biotechnology company that focuses on the development of oligonucleotide therapeutics for use in the treatment of severe neuromuscular and neurologic diseases.
More news about: Pomerantz LLP
Aug 06, 2025, 10:00 ET Pomerantz Law Firm Announces the Filing of a Class Action Against 3D Systems Corporation and Certain Officers - DDD
Medicine Program focuses on "the use of additive manufacturing for human organ transplantation." Since 2018, 3D Systems has partnered with the biotechnology company United Therapeutics Corporation ("United") "with a long-term goal of developing the capability to 3D print lungs that will allow patients
More news about: Pomerantz LLP
Aug 06, 2025, 08:31 ET MetaVia Extends 48 mg MAD Portion of Its Phase 1 Clinical Trial of DA-1726 for the Treatment of Obesity to 8 Weeks and Announces Fifth Weekly Dose in First Patient
Aug. 6, 2025 /PRNewswire/ -- MetaVia Inc. (Nasdaq: MTVA), a clinical-stage biotechnology company focused on transforming cardiometabolic diseases, today announced that it has extended to 8 weeks from 4 weeks, the 48 mg, multiple ascending
More news about: MetaVia Inc.
Aug 06, 2025, 08:30 ET AI in Bioprocessing Today -- Accelerate. Predict. Deliver., Upcoming Webinar Hosted by Xtalks
the global life science, food, healthcare and medical device communities. Every year, thousands of industry practitioners (from pharmaceutical, biotechnology, food, healthcare and medical device companies, private & academic research institutions, healthcare centers, etc.) turn to Xtalks for access
More news about: Honeycomb Worldwide Inc.
Aug 06, 2025, 08:00 ET Continuity Biosciences Appoints Josephine Torrente and Joseph DeSimone, PhD to Board of Directors
McNamara, P.C., the largest dedicated FDA regulatory law firm in the U.S.Experience: Over 30 years advising pharmaceutical and biotechnology companies on FDA regulatory strategy, product development, and lifecycle managementStrategic Contribution: Ms. Torrente's deep regulatory
More news about: Continuity Biosciences LLC
Aug 06, 2025, 08:00 ET Continuity Biosciences Appoints Josephine Torrente and Joseph DeSimone, PhD to Board of Directors
McNamara, P.C., the largest dedicated FDA regulatory law firm in the U.S.Experience: Over 30 years advising pharmaceutical and biotechnology companies on FDA regulatory strategy, product development, and lifecycle managementStrategic Contribution: Ms. Torrente's deep regulatory
More news about: Continuity Biosciences LLC
Aug 06, 2025, 06:59 ET Q32 Bio Reports Second Quarter 2025 Financial Results and Provides Corporate Update
Aug. 6, 2025 /PRNewswire/ -- Q32 Bio Inc. (Nasdaq: QTTB) ("Q32 Bio"), a clinical stage biotechnology company focused on developing innovative therapies for alopecia areata (AA) and other autoimmune and inflammatory diseases, today reported financial
More news about: Q32 Bio
Aug 06, 2025, 06:45 ET Mallinckrodt Names Christiana Stamoulis as President and Chief Financial Officer
will make significant contributions to our growth and continued success." Ms. Stamoulis has approximately 30 years of experience in the biotechnology industry. Prior to Incyte, she was President and CFO of Unum Therapeutics and, before that role, served as Senior Vice President of Corporate Strategy
More news about: Mallinckrodt plc
Aug 06, 2025, 06:30 ET BIO-TECHNE DECLARES DIVIDEND
acceptance of new products, the funding and focus of the types of research by the Company's customers, the impact of the growing number of producers of biotechnology research products and related price competition, general economic conditions, customer site closures or supply chain issues, the impact of currency
More news about: Bio-Techne Corporation